Trials / Completed
CompletedNCT00068029
Pegvisomant And Sandostatin LAR Combination Study
A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegvisomant/ Sandostatin LAR | |
| DRUG | Sandostatin LAR | |
| DRUG | Pegvisomant |
Timeline
- Start date
- 2003-10-01
- Completion
- 2006-05-01
- First posted
- 2003-09-05
- Last updated
- 2008-04-07
Locations
33 sites across 12 countries: United States, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Netherlands, Norway, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00068029. Inclusion in this directory is not an endorsement.